Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of ABT-414 in glioblastoma multiforme
NL-OMON41552Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2014
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of depatuxizumab mafodotin in glioblastoma (GBM) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Safety of ABT-414 with radiation and temozolomide, Maximum tolerated dose and 6 more. Started Jan 2014; status: active, not recruiting.
02
Drugs
depatuxizumab mafodotin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON41552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41552.